TERGENE BIOTECH
(TERGENE BIOTECH LIMITED)
Founded in 2008
About TERGENE BIOTECH
Tergene Biotech Limited is an innovative biotechnology startup specializing in the development of vaccines and biotherapeutics. They have successfully created platform technologies for novel vaccine candidates. In addition, Tergene supports various biotech companies and research institutions by supplying them with CRM197 carrier protein, which is primarily used in conjugate vaccines and cancer research.
Public Links of TERGENE BIOTECH
Frequently Asked Questions (FAQ)
When was TERGENE BIOTECH founded?
TERGENE BIOTECH was founded in the year 2008.
What is the legal name of TERGENE BIOTECH?
The legal name of TERGENE BIOTECH is Tergene Biotech Limited.
Who are the founders of TERGENE BIOTECH?
TERGENE BIOTECH is founded by Kuppusamy Sathyan and Mosuvan Kuppusamy.
What are the focus areas of TERGENE BIOTECH?
Who are TERGENE BIOTECH's competitors?
Possible competitors of TERGENE BIOTECH may include Biotide Solutions, Composite Interceptive Med-science Laboratories (Cimed), Immuneel Therapeutics and 7 others.
Get Access to Complete Information
Signup NowYNOS is not associated with any of the entities (organisations / people) mentioned in this page. Information provided here has been curated from multiple public as well as proprietary sources. All efforts have been taken to make it accurate and complete. If details are insufficient or not accurate, kindly suggest edits
Try StartupGPT, an AI-Assistant for Founders & Investors
Your conversational companion for Indian Startups, Funding, and much more.
Get more information with Incubators
The Ultimate Platform for Finding the Right Incubator and Accelerator.
Get more information with Insight
The most powerful dashboard solution on Indian Startups & Investors.
Get more information with Govt. Funding
Discover & analyse the best government funding avenues for your startup in India.
Get more information with Debt Funding
Discover Top Loan & Debt Funding Schemes for Startups in India.
- slide 1 of 8, currently active
- slide 2 of 8
- slide 3 of 8
- slide 4 of 8
- slide 5 of 8
- slide 6 of 8
- slide 7 of 8
- slide 8 of 8
